Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;186(1):143-149.
doi: 10.1007/s11845-016-1484-9. Epub 2016 Jul 28.

The role of laparoscopic sleeve gastrectomy as a treatment for morbid obesity; review of outcomes

B M Moloney  1 , D A Hynes  2 , M E Kelly  2 , A Iqbal  2 , E O'Connor  3 , D Lowe  4 , O J McAnena  2   3
Affiliations

The role of laparoscopic sleeve gastrectomy as a treatment for morbid obesity; review of outcomes

B M Moloney et al. Ir J Med Sci. 2017 Feb.

Abstract

Background: Global prevalence of obesity has soared. Where lifestyle and medical treatments have failed, laparoscopic sleeve gastrectomy (LSG) is increasingly regarded as a good surgical procedure for morbid obesity. Following the introduction of LSG, we assessed our surgical outcomes.

Methods: We reviewed a consecutive series of LSGs from January 2009 to January 2015. Our primary focus was to assess the success of this procedure on the percentage excess body weight loss (%EWL), Body Mass Index (BMI), hypertension and diabetes. Additionally, we evaluated the rate of procedure-related complications.

Results: There were 183 consecutive patients evaluated. Median age was 45 years (24-73). The majority were female (73.2 %, n = 134). At 1 year post-op, median %EWL was 57.6 %. There was an associated median reduction in BMI of 16 kg/m2 (0-33). At 2 years, median %EWL was sustained at 58.4 %. The median reduction in BMI was 16 kg/m2 (4-32). At 2-year post-op, 78.9 % of diabetic patients had their diabetic medications completely discontinued, while a further 15.8 % having their medication reduced. 34.6 % of hypertensive patients had their antihypertensives discontinued, with 50 % having medications reduced. There was no procedure related mortality. 3.3 % (n = 6) of patients had a confirmed staple-line leak.

Conclusion: This study shows LSG is a safe and successful management strategy for morbid obesity. In addition to the direct effects of sustained weight loss, it highlights indirect effects that LSG has on obesity-related health issues, with substantial reduction in diabetic and anti-hypertensive medications. Our results reaffirm international studies of the beneficial effects of LSG on Type II diabetes and hypertension.

Keywords: Minimally invasive surgery; Obesity; Sleeve gastrectomy; Surgical outcomes.

PubMed Disclaimer

References

    1. Ir J Med Sci. 2010 Mar;179(1):23-7 - PubMed
    1. Lancet. 2012 Dec 15;380(9859):2224-60 - PubMed
    1. Surg Endosc. 2007 Oct;21(10):1810-6 - PubMed
    1. Lancet Diabetes Endocrinol. 2015 Apr;3(4):232-4 - PubMed
    1. Best Pract Res Clin Anaesthesiol. 2011 Mar;25(1):11-25 - PubMed

LinkOut - more resources